Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives $15.50 Consensus PT from Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.50.

Several research analysts have commented on EPRX shares. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Cantor Fitzgerald increased their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Finally, Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th.

Eupraxia Pharmaceuticals Stock Down 2.5%

Shares of EPRX stock opened at $7.50 on Friday. The firm has a market capitalization of $269.70 million, a price-to-earnings ratio of -8.62 and a beta of 1.27. The stock has a fifty day moving average of $8.30 and a 200 day moving average of $6.80. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Guardian Wealth Advisors LLC NC purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth $76,000. Aptus Capital Advisors LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter worth $76,000. Quadrature Capital Ltd purchased a new position in Eupraxia Pharmaceuticals during the second quarter valued at $61,000. TCI Wealth Advisors Inc. purchased a new position in Eupraxia Pharmaceuticals during the third quarter valued at $65,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at $71,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.